Follow up of the 987 blood donors found with hepatitis C virus infection over 9-18years

Hepatology Research

Volumn 42, Issue 7, 2012, Pages 637-647

  Matsuo, Junko ^a   Mizui, Masaaki ^b   Okita, Hajime ^b   Katayama, Keiko ^a   Aimitsu, Shiomi ^c   Sakata, Tatsuro ^d   Obayashi, Makoto ^e   Nakanishi, Toshio ^f   Chayama, Kazuaki ^a   Miyakawa, Yuzo ^h   Yoshizawa, Hiroshi ^g   Tanaka, Junko ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Hiroshima Red Cross Blood Center   (Japan)

^c ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION FUKUYAMA MEDICAL CENTER   (Japan)

^e Onomichi General Hospital   (Japan)

^f Miyoshi Central Hospital   (Japan)

^g HIROSHIMA UNIVERSITY   (Japan)

^h Miyakawa Memorial Research Foundation   (Japan)

Author keywords

Alanine aminotransferase; Chronic hepatitis C; Hepatitis C virus; Hepatocellular carcinoma; Interferon; Natural history

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD DONOR; CANCER RISK; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL CLEARANCE;

EID: 84862265662     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.00966.x     Document Type: Article

References (29)

1. World Health Organization Media Center. Fact sheet Hepatitis C. [Cited August 2011.] Available from URL:
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-46.
3. Alberti A, Chemello L, Cavalletto D etal. Antibody to hepatitis C virus and liver disease in volunteer blood donors. Ann Intern Med 1991; 114: 1010-12.
4. Conry-Cantilena C, VanRaden M, Gibble J etal. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-6.
5. Esteban JI, Lopez-Talavera JC, Genesca J etal. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991; 115: 443-9.
6. Irving WL, Neal KR, Underwood JC, Simmonds PN, James V. Chronic hepatitis in United Kingdom blood donors infected with hepatitis C virus. BMJ 1994; 12 (308): 695-6.
7. Salmeron FJ, Palacios A, Perez-Ruiz M etal. Epidemiology, serological markers, and hepatic disease of anti-HCV ELISA-2-positive blood donors. Dig Dis Sci 1996; 41: 1933-8.
8. Serfaty L, Nousbaum JB, Elghouzzi MH, Giral P, Legendre C, Poupon R. Prevalence, severity, and risk factors of liver disease in blood donors positive in a second-generation anti-hepatitis C virus screening test. Hepatology 1995; 21: 725-9.
9. Yuki N, Hayashi N, Takehara T etal. Serum hepatitis C virus RNA levels and liver injury in volunteer blood donors. Am J Gastroenterol 1994; 89: 1462-6.
10. Mizui M, Tanaka J, Katayama K etal. Liver disease in hepatitis C virus carriers identified at blood donation and their outcomes with or without interferon treatment: Study on 1019 carriers followed for 5-10 years. Hepatol Res 2007; 37: 994-1001.
11. Okamoto H, Okada S, Sugiyama Y etal. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 1990; 60: 215-22.
12. Okamoto H, Sugiyama Y, Okada S etal. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673-9.
13. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
14. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
15. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
16. Thomas DL, Thio CL, Martin MP etal. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
17. Tanaka J, Mizui M, Nagakami H etal. Incidence rates of hepatitis B and C virus infections among blood donors in Hiroshima, Japan, during 10 years from 1994 to 2004. Intervirology 2008; 51: 33-41.
18. Prati D, Zanella A, Zanuso F etal. Sustained response to interferon-alpha2a monotherapy of young blood donors with minimal-to-mild chronic hepatitis C. J Viral Hepat 2000; 7: 352-60.
19. Zeuzem S, Diago M, Gane E etal. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-32.
20. Puoti C, Pellicelli AM, Romano M etal. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study. Liver Int 2009; 29: 1479-84.
21. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
22. Cividini A, Rebucci C, Silini E, Mondelli MU. Is the natural history of hepatitis C virus carriers with normal aminotransferase really benign? Gastroenterology 2001; 121: 1526-7.
23. Ryan KE, MacLennan S, Barbara JA, Hewitt PE. Follow up of blood donors positive for antibodies to hepatitis C virus. BMJ 1994; 308: 696-7.
24. Tanaka J, Koyama T, Mizui M etal. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology 2011; 54: 185-95.
25. Yoshizawa H, Tanaka J, Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology 2006; 49: 7-17.
26. Tanaka J, Kumada H, Ikeda K etal. Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol 2003; 70: 378-86.
27. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36: S74-83.
28. Ikeda K, Saitoh S, Arase Y etal. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-30.
29. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-41.